DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Myrbetriq (Mirabegron) - Summary

 
 



MYRBETRIQ SUMMARY

Mirabegron is a beta-3 adrenergic agonist.

Myrbetriq ® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.


See all Myrbetriq indications & dosage >>

NEWS HIGHLIGHTS

Clinical Trials Related to Myrbetriq (Mirabegron)

A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB) [Active, not recruiting]
The purpose of this study is to assess tolerability of Myrbetriq compared to Detrol LA in the treatment of subjects with Overactive Bladder (OAB). This study will also assess patient preference, safety and tolerability of Myrbetriq and Detrol LA in subjects with symptoms of OAB as well as the impact of treatment on micturition frequency and incontinence episodes.

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron [Completed]
The purpose of this study is to assess the pharmacokinetics of three doses of oral mirabegron formulations with three different release rates versus three doses of mirabegron administered intravenously; to study safety and side effects of the oral and IV doses of mirabegron.

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder [Active, not recruiting]
The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects [Completed]
The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder [Enrolling by invitation]
The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.

more trials >>


Page last updated: 2014-07-25

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017